{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:20:32Z","timestamp":1772763632984,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,13]],"date-time":"2018-05-13T00:00:00Z","timestamp":1526169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["FISM2013\/R\/13"],"award-info":[{"award-number":["FISM2013\/R\/13"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10072-018-3440-0","type":"journal-article","created":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T23:05:25Z","timestamp":1526166325000},"page":"1467-1470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod"],"prefix":"10.1007","volume":"39","author":[{"given":"L.","family":"Ferre\u2019","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Clarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sferruzza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mascia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sangalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Dalla Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aboulwafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Martinelli Boneschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,13]]},"reference":[{"issue":"23","key":"3440_CR1","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","volume":"296","author":"KL Munger","year":"2006","unstructured":"Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23):2832\u20132838","journal-title":"JAMA"},{"issue":"2","key":"3440_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1352458513494959","volume":"20","author":"V Martinelli","year":"2014","unstructured":"Martinelli V, Dalla Costa G, Colombo B, Dalla Libera D, Rubinacci A, Filippi M, Furlan R, Comi G (2014) Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 20(2):147\u2013155","journal-title":"Mult Scler"},{"key":"3440_CR3","doi-asserted-by":"publisher","unstructured":"Tuzun1 E, Kucukhuseyin O, Kurtuncu M et al (2015) Reduced serum vitamin D levels in neuromyelitis optica. Neurol Sci 36(9):1701\u20131702. \n                    https:\/\/doi.org\/10.1007\/s10072-015-2229-7","DOI":"10.1007\/s10072-015-2229-7"},{"issue":"3","key":"3440_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1212\/WNL.0b013e31825fdec7","volume":"79","author":"TF Runia","year":"2012","unstructured":"Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ (2012) Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 79(3):261\u2013266","journal-title":"Neurology"},{"issue":"3","key":"3440_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","volume":"71","author":"A Ascherio","year":"2014","unstructured":"Ascherio A, Munger KL, White R, K\u00f6chert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalb\u00e1n X, Edan G, Barkhof F, Pleimes D, Rad\u00fc EW, Sandbrink R, Kappos L, Pohl C (2014) Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 71(3):306\u2013314","journal-title":"JAMA Neurol"},{"issue":"12","key":"3440_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1001\/jamaneurol.2015.2742","volume":"72","author":"KC Fitzgerald","year":"2015","unstructured":"Fitzgerald KC, Munger KL, Kochert K et al (2015) Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol 72(12):1458\u20131465","journal-title":"JAMA Neurol"},{"issue":"6","key":"3440_CR7","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1212\/NXI.0000000000000167","volume":"2","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz B, Chitnis T (2015) Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm 2(6):e167","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"3440_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302","journal-title":"Ann Neurol"},{"key":"3440_CR9","first-page":"3","volume":"615","author":"CI Bliss","year":"1958","unstructured":"Bliss CI (1958) Periodic regression in biology and climatology. Conn Agric Exp Station 615:3\u201355","journal-title":"Conn Agric Exp Station"},{"key":"3440_CR10","volume-title":"High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a","author":"R Hupperts","year":"2016","unstructured":"Hupperts R (2016) High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a. ECTRIMS congress, London"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-018-3440-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T23:31:36Z","timestamp":1557790296000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-018-3440-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,13]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["3440"],"URL":"https:\/\/doi.org\/10.1007\/s10072-018-3440-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,13]]},"assertion":[{"value":"8 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article:L. Ferre\u2019 reports no disclosures.F. Clarelli reports no disclosures.G. Sferruzza reports no disclosures.M.A. Rocca received speaker\u2019s honoraria from Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, Teva, and Merk Serono and receives research support from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla.E. Mascia reports no disclosures.M. Radaelli reports no disclosures.F. Sangalli reports no disclosures.G. Dalla Costa reports no disclosures.L. Moiola received honoraria for speaking at meetings or for attending to advisory board from Sanofi-Genzyme, Biogen-Idec, Novartis, and TEVA.M. Aboulwafa reports no disclosures.F. Martinelli Boneschi has received compensation for activities with Teva Neuroscience, Biogen Idec, and Merck Serono as speaker and\/or advisor.G. Comi has received compensation for consulting services with the following companies: Novartis, Teva, Sanofi, Genzyme, Merck, Biogen, Excemed, Roche, Almirall, Chugai, Receptos, Forward Pharma and compensation for speaking activities from Novartis, Teva, Sanofi, Genzyme, Merk, Biogen, Excemed, and Roche.M. Filippi is Editor-in-Chief of the Journal of Neurology; serves on a scientific advisory board for Teva Pharmaceutical Industries; has received compensation for consulting services and\/or speaking activities from Biogen Idec, ExceMED, Novartis, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer\u2019s Drug Discovery Foundation (ADDF), the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA).V. Martinelli has received honoraria for consulting and speaking activities from Biogen-Idec, Merck, Bayer, TEVA, Novartis, and Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}